Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Recruiting · NCT07484022 · Registry updated 2026-06-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, nervous system disorder, neuromuscular disease, peripheral nervous system disorder, transitional cell carcinoma | Recruiting | Phase 1 | 2026-06-18 | NCT07484022 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Generate Biomedicines | 6 |
10 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| COH Atlanta | Tucker | United States | 1 |
| COH Chicago | Zion | United States | 1 |
| COH Lennar | Irvine | United States | 1 |
| MDACC | Houston | United States | 5 |
| MSK | New York | United States | 1 |
| Orlando Health | Orlando | United States | 64 |
| Rutgers | New Brunswick | United States | 1 |
| Start New York, LLC | Lake Success | United States | 1 |
| The University of Virgina | Charlottesville | United States | 1 |